Host: Scott Kopetz, MD, PhD 

 Host: Cathy Eng, MD, FACP 


 
 This series provides expert perspectives on the management of metastatic colorectal cancer (mCRC), with a focus on the timing and methodology of molecular testing, targeted treatment combinations for BRAF-mutant mCRC, and the management of treatment-related adverse events.

Host: Scott Kopetz, MD, PhD Host: Cathy Eng, MD, FACP This series provides expert perspectives on the management of metastatic colorectal cancer (mCRC), with a focus on the timing and methodology of molecular testing, targeted treatment combinations for BRAF-mutant mCRC, and the management of treatment-related adverse events.

Host: Scott Kopetz, MD, PhD 

 Host: Cathy Eng, MD, FACP 


 
 This series provides expert perspectives on the management of metastatic colorectal cancer (mCRC), with a focus on the timing and methodology of molecular testing, targeted treatment combinations for BRAF-mutant mCRC, and the management of treatment-related adverse events.

Advancing Molecular Therapies to First Line in BRAF-Mutated mCRC: Insights From Emerging Data

Your professional development is critical to the care of your patients. Stay on top of the latest treatments and information with ReachMD's CME activities. Our topics span cardiology, diabetes, oncology, women's health and more. And our CME library is continuously growing, every quarter.

Share Advancing Molecular Therapies to First Line in BRAF-Mutated mCRC: Insights From Emerging Data

Sign up to save your podcasts

Advancing Molecular Therapies to First Line in BRAF-Mutated mCRC: Insights From Emerging Data

Advancing Molecular Therapies to First Line in BRAF-Mutated mCRC: Insights From Emerging Data